The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRASG12C Inhibitors.

Abstract excerpt

Inhibitors of KRASG12C that bind the target in its inactive conformation and lock it in off-mode have shown early signs of clinical activity in patients with KRAS G12C-mutant lung cancer, but responses tend to be short-lived and invariably prelude the development of acquired resistance through largely unexplored mechanisms. A new study describes the emergence of RAS-MAPK heterogeneous subclonal alterations in a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Neoplasms
• Share to Mutation
• Share to Proto-Oncogene Proteins p21(ras)